Walleye Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$655K Buy
+1,300
New +$687K ﹤0.01% 3863
2026
Q2
– Sell
-1,300
Closed -$681K – 5012
2026
Q1
$681K Buy
1,300
+700
+117% +$334K ﹤0.01% 2417
2025
Q4
$349K Sell
600
-2,100
-78% -$1.07M ﹤0.01% 3193
2025
Q3
$1.24M Buy
2,700
+2,300
+575% +$858K ﹤0.01% 1933
2025
Q2
$121K Buy
400
+100
+33% +$29.8K ﹤0.01% 3677
2025
Q1
$99.4K Buy
+300
New +$98.6K ﹤0.01% 3628
2024
Q3
– Sell
-400
Closed -$112K – 5647
2024
Q2
$112K Buy
400
+200
+100% +$47.6K ﹤0.01% 4661
2024
Q1
$53.4K Buy
+200
New +$47.1K ﹤0.01% 4654
2023
Q2
– Sell
-1,000
Closed -$242K – 4652
2023
Q1
$242K Buy
+1,000
New +$272K ﹤0.01% 2307
2020
Q1
– Sell
-900
Closed -$82K – 1372
2019
Q4
$82K Buy
+900
New +$87.3K 0.01% 1407
2019
Q2
– Sell
-5,400
Closed -$676K – 1916
2019
Q1
$676K Buy
+5,400
New +$671K 0.11% 280

Other funds holding MDGL

Walleye Capital's MDGL Position: Q3 2026 in Review

Walleye Capital opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 366 shares worth $184K. The stake represents ﹤0.01% of the portfolio and ranks #4870 among its holdings. This is a return to the name: Walleye Capital previously reported a position in MDGL as recently as Q1 2026.

Walleye Capital first reported a position in MDGL in Q4 2019 and has held it in 7 quarters since. The position peaked at $6.92M in Q1 2026. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Walleye Capital held 366 shares of Madrigal Pharmaceuticals worth $184K as of Q3 2026.
  • Madrigal Pharmaceuticals was a new Walleye Capital position in Q3 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #4870 holding.
  • Walleye Capital first reported a position in Madrigal Pharmaceuticals in Q4 2019 and has held it in 7 quarters since.
  • Walleye Capital's Madrigal Pharmaceuticals position peaked at $6.92M in Q1 2026.
  • 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.